Pioglitazone--where do we stand in India?
Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Chennai.
Viswanathan
V
Mohan
Sharad
S
Bedi
Ranjit
R
Unnikrishnan
Binode Kumar
BK
Sahay
Shashank
S
Joshpi
Anoop
A
Misra
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007194:India; D007333:Insulin Resistance; D000077205:Pioglitazone; D018570:Risk Assessment; D045162:Thiazolidinediones / Q000009:adverse effects*; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced*
D045162:Thiazolidinediones; D000077205:Pioglitazone